~~U.S.~~UNITED ~~SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q~~STATES

~~Mark One [ X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE~~ SECURITIES ~~EXCHANGE~~AND ~~ACT OF 1934 For the period ended June 30, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES~~ EXCHANGE ~~ACT OF 1934 For the transition period from ______ to _______~~COMMISSION

~~Commission~~Washington, ~~File~~DC ~~No. 000-52703~~20549

Genova Biotherapeutics Inc. (Name of small business issuer in its charter)
Nevada (State or other jurisdiction of incorporation or organization)	20-4939361 (I.R.S. Employer Identification No.)
1461 A. First Avenue, Suite 360 New York, NY (Address of principal executive offices)
Kinder Travel Inc. 1461 A. First Avenue, Suite 360 New York, NY (Name and address if changed from prior report)
(646) 845-1920 (Issuer’s telephone number)
Securities registered pursuant to Section 12(b) of the Act:	Name of each exchange on which registered:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $0.001
(Title of Class)

FORM 10-Q

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X ] No[ ]

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended September 30, 2009

[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from __________ to __________

	Commission File Number: 000-52703

~~Indicate~~Genova ~~by check mark whether the registrant has submitted electronically and posted on its corporate Web site~~Biotherapeutics, ~~if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 229~~Inc.~~405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes [ ] No[ ] N/A [X ]~~

(Exact name of Registrant as specified in its charter)

Nevada	20-4939361
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

1461 A. First Avenue, Suite 360 New York, NY

(Address of principal executive offices)

(646) 845-1920

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [ ] Yes [ X] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

[ ] Large accelerated filer Accelerated filer	[ ] Non-accelerated filer
[X] Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [X] Yes [ ] No

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 307,296,125 common shares as of April 9, 2010.

Table of Contents

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	10
Item 4T:	Controls and Procedures	10
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	11
Item 1A:	Risk Factors	11
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3:	Defaults Upon Senior Securities	11
Item 4:	Submission of Matters to a Vote of Security Holders	11
Item 5:	Other Information	11
Item 6:	Exhibits	11

Indicate by check mark whether the registrant is a large accelerated filed, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer [ ] Accelerated filer [ ]

Non-accelerated filer [ ] Smaller reporting company [X]

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years. N/A

Indicate by checkmark whether the issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes[ ] No[ ] N/A [X ]

Applicable Only to Corporate Registrants

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most practicable date:

Class	Outstanding as of August 10, 2009
Common Stock, $0.001	307,296,125

Table of Contents

Genova Biotherapeutics, Inc. (Formerly known as Kinder Travel Inc.) Table of Contents

		Page
Part 1.	FINANCIAL INFORMATION
Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14
Item 4.	Controls and Procedures	14
Part II.	OTHER INFORMATION
Item 1.	Legal Proceedings	15
Item 1A.	Risk Factors	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	16
Item 3.	Defaults Upon Senior Securities	16
Item 4.	Submission of Matters to a Vote of Security Holders	16
Item 5.	Other Information	17
Item 6.	Exhibits	18

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Our financial statements included in this Form 10-Q are as follows:
F-1	Balance Sheets as of September 30, 2009 (unaudited) and December 31, 2008 (audited);
F-2	Statements of Operations for the three and nine months ended September 30, 2009 and 2008, and for the period from July 1, 2009 (inception of current operations) to September 30, 2009 (unaudited);
F-3	Statements of Cash Flows for the nine months ended September 30, 2009 and 2008, and for the period from July 1, 2009 (inception of current operations) to September 30, 2009 (unaudited);
F-4	Notes to Financial Statements;

These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended September 30, 2009 are not necessarily indicative of the results that can be expected for the full year.

PART I

ITEM 1. FINANCIAL STATEMENTS

Genova Biotherapeutics, Inc.
(Formerly known as Kinder Travel Inc.)
Balance Sheets
(In Canadian Dollars)
		June 30, 2009		December 31, 2008
ASSETS		(Unaudited)
Current Assets
Cash	$	28,884	$	21,220
Accounts receivable, net of allowance for doubtful accounts		6,165		-
Total Current Assets		35,049		21,220
Other Assets
Intellectual Property - Medical Patents		92,573		-
Vehicles and Equipment, net of accumulated depreciation		16,467		21,957
Website, net of accumulated depreciation		592		1,777
Travel Agency Bond		15,000		15,000
Total Other Assets		124,632		38,734
TOTAL ASSETS	$	159,681	$	59,954
LIABILITIES
Current Liabilities
Accounts payable	$	45,239	$	37,157
Accrued liabilities		2,906		4,286
Payroll Liabilities		2,470		2,085
Sales Tax Payable		613		105
Customer Prepayments		-		310
Shareholders' Loans		41,759		31,273
Current Portion of long-term debt		19,860		1,136
Total Current Liabilities		112,847		76,352
Long Term Liabilities
Loan payable		-		19,282
Total Long Term Liabilities		-		19,282
TOTAL LIABILITIES		112,847		95,634
STOCKHOLDERS’ EQUITY (DEFICIT)
Capital Stock
Preferred Stock
Authorized: 10,000,000 shares with $0.00001 par value. Issued: Nil		-		-
Common Stock
Authorized: 990,000,000 common shares with $0.00001 par value
Issued: 331,250,000 (Jun 30/09); 300,000,000 (Dec 31/08)		3,750		3,364
Additional paid-in capital		223,036		129,436
Accumulated Other Comprehensive Income		848		(855)
Retained Earnings		(180,800)		(167,625)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)		46,834		(35,680)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$	159,681	$	59,954
The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

GENOVA BIOTHERAPEUTICS, INC.

(formerly Kinder Travel Inc.)

(A development stage company)

Balance sheets

(Expressed in Canadian dollars)

	September 30, 2009 $		December 31, 2008 $
	(unaudited)		(audited)
ASSETS

Current assets

Cash		25,204		21,220
Due from director (Note 5)		4,413		–

Total current assets		29,617		21,220

Intangible assets (Note 4)		81,257		–
Long-term assets of discontinued operations		–		38,734

Total assets		110,874		59,954

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current liabilities

Accounts payable		21,073		14,077
Accrued liabilities		2,906		4,286
Due to related parties (Note 5)		36,673		31,272
Current liabilities of discontinued operations		–		26,717

Total current liabilities		60,652		76,352

Long-term liabilities of discontinued operations		–		19,282

Total liabilities		60,652		95,634

Stockholders’ equity (deficit)

Preferred stock Authorized: 10,000,000 shares, par value US$0.001 Issued and outstanding: Nil shares		–		–

Common stock Authorized: 990,000,000 shares, par value US$0.00001 Issued and outstanding: 307,296,125 shares (2008 – 300,000,000 shares)		3,446		3,364

Additional paid-in capital		223,363		129,436

Accumulated other comprehensive loss		–		(855)

Accumulated deficit		(180,800)		(167,625)

Retained earnings during the development stage		4,213		–

Total stockholders’ equity (deficit)		50,222		(35,680)

Total liabilities and stockholders’ equity (deficit)		110,874		59,954

(The accompanying notes are an integral part of these financial statements)

F-1

Table of Contents

GENOVA BIOTHERAPEUTICS, INC.

(formerly Kinder Travel Inc.)

(A development stage company)

Statements of operations

(Expressed in Canadian dollars)

(unaudited)

	Three Months Ended September 30,				Nine Months Ended September 30,				Accumulated from July 1, 2009 to September 30,
	$	2009	$	2008	$	2009	$	2008	$	2009

Revenue		–		–		–		–

Expenses

Professional fees		(187)		1,576		13,868		4,906		(187)
Transfer agent and filing fees		1,482		7,992		13,752		7,992		1,482

Total expenses		1,295		9,568		27,620		12,898		1,295

Net loss before other income		(1,295)		(9,568)		(27,620)		(12,898)		(1,295)

Other income

Foreign exchange gain		5,508		–		3,362		–		5,508

Net income (loss) from continuing operations		4,213		(9,568)		(24,258)		(12,898)		4,213

Discontinued operations (Note 3)		–		(16,743)		15,296		(14,415)		–

Net income (loss) for the period		4,213		(26,311)		(8,962)		(27,313)		4,213

Other comprehensive income (loss)

Foreign currency translation adjustments		(848)		392		855		(19)		(848)

Comprehensive income (loss)		3,365		(25,919)		(8,107)		(27,332)		3,365

Net loss per share, basic and diluted
Continuing operations		–		–		–		–
Discontinued operations		–		–		–		–

		–		–		–		–

Weighted average number of shares outstanding		312,503,489		300,000,000		312,340,919		300,000,000

(The accompanying notes are an integral part of these financial statements)

F-2

Table of Contents

GENOVA BIOTHERAPEUTICS, INC.

(formerly Kinder Travel Inc.)

(A development stage company)

Statements of cash flows

(Expressed in Canadian dollars)

(unaudited)

	Nine Months Ended September 30,		Nine Months Ended September 30,		Accumulated from July 1, 2009 to September 30,
	$	2009	$	2008	$	2009

Operating activities

Net income (loss) from continuing operations for the period		(24,258)		(12,898)		4,213

Changes in operating assets and liabilities:

Accounts payable and accrued liabilities		5,616		6,150		(1,219)

Net cash provided by (used in) operating activities		(18,642)		(6,748)		2,994

Financing activities

Advances from related parties		18,554		5,267		–
Repayment of related party loans		(9,000)		–		(5,826)

Net cash provided by financing activities		9,554		5,267		(5,826)

Net cash provided by discontinued operations		12,217		9,807		–

Effect of exchange rate changes on cash		855		(19)		(848)

Change in cash		3,984		8,307		(3,680)

Cash, beginning of period		21,220		16,275		28,884

Cash, end of period		25,204		24,582		25,204

Non-cash investing and financing activities:
Common stock issued for the acquisition of intangible assets		81,257		–		–
Net liabilities of travel business assumed by a director recorded as additional paid-in capital		12,753		–		12,753

Supplemental disclosures:
Interest paid		–		–		–
Income taxes paid		–		–		–

(The accompanying notes are an integral part of these financial statements)

F-3

Table of Contents

GENOVA BIOTHERAPEUTICS, INC.

(formerly Kinder Travel Inc.)

(A development stage company)

Notes to the financial statements

September 30, 2009

(Expressed in Canadian dollars)

(unaudited)

1.	Basis of Presentation

Kinder Travel Inc. (the “Company”) was incorporated in the State of Nevada. The Company changed its name to Genova Biotherapeutics Inc. on April 24, 2009. Effective July 1, 2009, the Company disposed of its travel business operations. Refer to Note 3.

The Company is now a biotechnological drug development company with a focus on identifying, evaluating and acquiring new promising drugs for treatment and prevention of oncological and infectious diseases in human beings. As the Company has changed its business and does not yet have any revenue generating operations, it has re-entered the development stage effective July 1, 2009.

The accompanying financial statements of the “Company should be read in conjunction with the financial statements and accompanying notes filed with the U.S. Securities and Exchange Commission in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008. In the opinion of management, the accompanying financial statements reflect all adjustments of a recurring nature considered necessary to present fairly the Company’s financial position and the results of its operations and its cash flows for the periods shown.

These financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any revenues since re-entering the development stage and is unlikely to generate earnings in the immediate or foreseeable future. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary equity financing to continue operations, and the attainment of profitable operations. As at September 30, 2009, the Company has a working capital deficit of $31,035 and accumulated losses since inception. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. The results of operations and cash flows for the periods shown are not necessarily indicative of the results to be expected for the full year.

2.	Recent Accounting Pronouncements

In June 2009, the Financial Accounting Standards Board (“FASB”) issued guidance now codified as FASB ASC Topic 105, Generally Accepted Accounting Principles as the single source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with U.S. GAAP, aside from those issued by the SEC. ASC 105 does not change current U.S. GAAP, but is intended to simplify user access to all authoritative U.S. GAAP by providing all authoritative literature related to a particular topic in one place. The adoption of ASC 105 did not have a material impact on the Company’s financial statements, but did eliminate all references to pre-codification standards.

F-4

Table of Contents

GENOVA BIOTHERAPEUTICS, INC.

(formerly Kinder Travel Inc.)

(A development stage company)

Notes to the financial statements

September 30, 2009

(Expressed in Canadian dollars)

(unaudited)

2.	Recent Accounting Pronouncements (continued)

In May 2009, FASB issued ASC 855, Subsequent Events, which establishes general standards of for the evaluation, recognition and disclosure of events and transactions that occur after the balance sheet date. Although there is new terminology, the standard is based on the same principles as those that currently exist in the auditing standards. The standard, which includes a new required disclosure of the date through which an entity has evaluated subsequent events, is effective for interim or annual periods ending after June 15, 2009. The adoption of ASC 855 did not have a material effect on the Company’s financial statements.

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

3.	Discontinued Operations

On April 20, 2009, the Company entered into an agreement to sell its travel business operations to a director of the Company. The director assumed all the assets and liabilities of the travel business in exchange for the return of 23,953,875 shares of common stock owned by the director to the Company. The shares were returned on July 20, 2009 and the effective date of the assumption of the travel business assets and liabilities was July 1, 2009.

The net liabilities of the travel business assumed by a director of the Company on July 1, 2009 were as follows:

	$

Accounts receivable		6,165
Property and equipment		16,467
Website development costs		592
Travel agency bond		15,000
Accounts payable and accrued liabilities		(26,030)
Loan payable		(19,861)
Due to director		(5,086)

		(12,753)

The net liabilities of $12,753 assumed were recorded as additional paid-in capital.

Results of operations for the discontinued travel business for the six months ended June 30, 2009 are as follows:

	$

Revenue, net		69,591
Automotive		(7,822)
Depreciation		(6,674)
General and administrative		(12,732)
Interest		(1,254)
Wages and benefits		(25,813)

Net income for the period		15,296

F-5

Table of Contents

GENOVA BIOTHERAPEUTICS, INC.

(formerly Kinder Travel Inc.)

(A development stage company)

Notes to the financial statements

September 30, 2009

(Expressed in Canadian dollars)

(unaudited)

4.	Intangible Assets

On April 15, 2009, the Company entered into an asset purchase agreement with Phoinos Oxford Lifesciences Limited (“Phoinos”), a company incorporated under the laws of the Federation of St. Kitts & Nevis, for the purchase of the right, title and interest in and to medical intellectual property. As payment, the Company issued 31,250,000 shares of its restricted common stock with a fair value of $81,257 into escrow. The shares will be subsequently transferred to Phoinos in ten quarterly installments.

5.	Related Party Transactions

a)	As at September 30, 2009, the Company is owed $4,413 from (December 31, 2008 - $13,153 due to) a director of the Company which is non-interest bearing, unsecured and due on demand.

b)	As at September 30, 2009, the Company owes $36,673 (December 31, 2008 - $18,119) to shareholders of the Company. The amounts due are non-interest bearing, unsecured and due on demand.

6.	Common Stock

a)	On April 20, 2009, the Company issued 31,250,000 common shares with a fair value of $81,257 for the purchase of the rights, title, and interest in medical intellectual property pursuant to an asset purchase agreement. Refer to Note 4.

b)	On April 24, 2009, the authorized share capital of the company was increased from 65,000,000 shares, par value of US$0.001, to 990,000,000 shares, par value US$0.00001. The share capital and additional paid-in capital amounts have been retroactively adjusted for all periods to reflect this change.

c)	On July 13, 2009, the Company completed a 125-for-1 forward stock split of the issued and outstanding common stock. All share amounts have been retroactively adjusted for all periods presented.

On July 20, 2009, a director and former officer of the Company returned 23,953,875 shares of common stock of the Company in exchange for the net liabilities of the Company’s travel business operations effective July 1, 2009 pursuant to an Asset Purchase Agreement dated April 20, 2009. The net liabilities assumed of $12,753 were recorded as additional paid-in capital.

7.	Subsequent Events

In accordance with ASC 855, “Subsequent Events”, the Company has evaluated subsequent events to April 5, 2010, the date the financial statements were available to be issued. During this period, the Company did not have any material recognizable subsequent events.

F-6

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “August,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview and Plan of Operations

We are currently a development stage company focused on identifying, evaluating and acquiring proprietary drugs for the treatment of oncological and infectious diseases in human beings. Currently, we hold the rights to pending patent applications for three medicines. Patent applications for each of the three drugs are pending in Denmark and the United Kingdom:

Prostate cancer treatment This invention relates to the use of short polypeptides for treatment of cancers and more particular for the treatment of prostate cancer. The invention provides methods and compositions comprising short polypeptides such as prostaganin for use as agents to kill prostate cancer cells.

Breast cancer treatment This invention aims to provide an effective treatment for patients suffering from cancer and more preferably from breast cancer using new lipid derivatives such as tetanolic acid.

Breast cancer treatment This invention concerns methods for the purification of undifferentiated state tumoral stem cells from solid breast carcinomas that are normally resistant to conventional therapies, aiming at devising new tumour markers and therapeutic targets both for early diagnosis and for targeted therapeutic strategies.

Our goal is to further develop these proprietary new treatments through joint ventures, strategic partnerships, licensing agreements, and similar arrangements. Currently, we are not a party to any ongoing joint ventures, strategic partnerships, or similar arrangements for the development of our patent-pending new medicines. Due to adverse publicity stemming from the SEC trading suspension and investigation, discussed below, our ability to form new partnerships for the development of our drugs has been severely impaired. We currently have no ability to move forward with any in-house research or development and no employees other than our Chief Executive Officer and Director, Aaron Whiteman, and our Secretary and Director, Dirk Holzhauer. We would require substantial additional financing in order to further develop our intellectual property or to sustain any substantial future business operations for any significant period of time. Although we are pursuing additional debt and/or private equity financing, we currently have no firm arrangements for any financing. Due to our removal from the Over-the-Counter-Bulletin Board and the open SEC investigation discussed below, we believe that our ability to obtain significant debt or equity financing will be impaired within the immediate future.

Genova Biotherapeutics, Inc.
(Formerly known as Kinder Travel Inc.)
Unaudited Statements of Operations
(In Canadian Dollars)
		For the Three		For the Three		For the Six		For the Six
		Months Ended		Months Ended		Months Ended		Months Ended
		June 30, 2009		June 30, 2008		June 30, 2009		June 30, 2008
Sales	$	58,851	$	67,860	$	125,698	$	139,405
Cost of Sales		22,553		17,447		55,517		32,148
Gross Margin		36,298		50,413		70,181		107,258
General and Administrative Expenses
Automobile Expense		3,941		3,314		7,822		6,663
Depreciation and Amortization		3,337		2,387		6,675		4,773
General and Administrative		8,460		19,012		14,564		32,258
Payroll Expenses		15,026		27,094		27,970		54,785
Professional Fees		8,949		1,608		14,055		9,780
Transfer Agent Fees		11,752		-		12,270		-
Total Expenses		51,465		53,414		83,356		108,259
Profit (Loss) from Operations		(15,167)		(3,001)		(13,175)		(1,002)
Provision for Income Tax		0		0		0		-
Net Operating Profit (Loss)	$	(15,167)	$	(3,001)	$	(13,175)	$	(1,002)
Comprehensive Income(Loss)
Net Profit (Loss)		(15,167)		(3,001)		(13,175)		(1,002)
Foreign currency translation adjustment		1,607		(617)		1,703		(411)
Total Comprehensive Income(Loss)	$	(13,560)	$	(3,618)	$	(11,472)	$	(1,412)
	$	(0.00)	$	(0.00)	$	(0.00)	$	(0.00)
Gain (Loss) per Share – Basic and Diluted
		326,098,901		300,000,000		313,121,547		300,000,000
Weighted Average Shares Outstanding
The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

At this time, our operations consist of acting as a holding company for the rights to the patent applications discussed above.

SEC Trading Suspension; Removal From The OTCBB

On September 23, 2009, the Securities and Exchange Commission suspended all trading in our common stock for the period from 9:30 a.m. EST, on September 23, 2009 through 11:59 p.m. EST, on October 6, 2009. As set forth in its Order of Suspension of Trading, the SEC determined that there was a lack of current and accurate information concerning our securities and operational activities. In addition, the SEC determined that questions had arisen regarding promotional activity for our stock and the adequacy and accuracy of press releases, financial statements, and statements on our website concerning our current financial condition, business and operations, and stock promoting activity.

On September 29, 2009, following the SEC trading suspension, the Financial Industry Regulatory Authority (“FINRA”) removed our stock from quotation from the Over-the-Counter-Bulletin Board (the “OTCBB”) for failure to comply with Rule 15c211. Promulgated under the Securities Exchange Act of 1934, Rule 15c211 requires securities brokers and dealers to possess certain information regarding an issuer and its securities before publishing any quotation for a security in any quotation medium, including the OTCBB. Our removal from the OTCBB was therefore a result of FINRA’s determination that the information required by the Rule was not being made properly available to its brokers and dealers.

Currently, bid and ask quotations for our common stock are not quoted on any exchange or quotation system, including the OTCBB or the Pink Sheets. Our common stock is a “grey market” security. Trades in grey market stocks are reported by broker-dealers to their Self Regulatory Organization (SRO) and the SRO distributes the trade data to market data vendors and financial websites so investors can track price and volume. Because grey market securities are not traded or quoted on an exchange or interdealer quotation system, investor's bids and offers are not collected in a central spot and market transparency is diminished. In addition, Pink OTC Markets Inc., the primary inter-dealer electronic quotation and trading system in the over-the-counter securities market, has labelled our stock “Caveat Emptor” and has blocked quotations of our common stock from its www.otcmarkets.com website.

SEC Investigation

Concurrently with its trading halt in September of 2009, the SEC opened a formal investigation regarding the company. We received a subpoena from the New York Regional Office of the SEC dated September 22, 2009. Through counsel, we have provided certain documentation to the SEC. Although, to our knowledge, no enforcement action has been commenced against the company, the SEC’s investigation remains open and pending.

Genova Biotherapeutics, Inc.
(Formerly known as Kinder Travel Inc.)
Unaudited Statements of Cash Flows
(In Canadian Dollars)
		For the Six Months Ended June 30, 2009		For the Six Months Ended June 30, 2008
Operating
Net Income (Loss)	$	(13,175)	$	(1,002)
Adjustments to reconcile net income (loss) to net cash flows used in operating activities
Depreciation and Amortization		6,675		4,773
Imputed interest of shareholders loans		1,413		-
Changes in operating assets and liabilities
Accounts receivable		(6,165)		(19,013)
Prepaid Expenses		0		2,682
Accounts payable		8,082		1,880
Accrued liabilities		(1,380)		-
Payroll Liabilities		385		-
Sales Tax Payable		508		-
Customer Prepayments		(310)		-
Net cash flows from (used for) operations		(3,967)		(10,680)
Financing
Borrowings on debt		19,907		113,135
Payments on debt		(9,979)		(104,040)
Net cash flows from financing activities		9,928		9,096
Effect of exchange rate changes		1,703		(411)
Change in Cash		7,664		(1,995)
Cash - Beginning		21,220		16,275
Cash - Ending	$	28,884	$	14,280
Supplemental Cash Flow Information
Cash paid for:
Income Taxes	$	-	$	-
Interest	$	-	$	-
Non Cash Transactions
Stock issued to acquire patents	$	92,573	$	-

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Corrections, Updates and Clarifications to Prior Press Releases

From the inception of our current operations on July 1, 2009 through the SEC trading suspension discussed above, a series of press releases regarding the company were issued by investor relations firms. Some of these press releases contain inaccurate and/or unauthorized statements, or statements which should be clarified in light of subsequent developments.

A press release announcing the appointment of our CEO, Aaron Whiteman, incorrectly stated that he was a graduate of the London School of Economics. Mr. Whiteman is a graduate of Oxford University and did not attend the London School of Economics. In addition, the press release stated that Mr. Whiteman had “worked with” various listed companies. Mr. Whiteman has not worked for or directly with the companies listed in the press release.

A press release regarding the company’s prostaganin-based cancer treatment stated that the company “filed a patent.” The company filed a patent application, which remains pending. No patent has been issued. The press release also states that licensing to various companies “could prove to be extremely lucrative.” This statement was speculative in nature; no licensing agreements with the listed companies are or were in place.

A press release related to Dr. Anders Boegh Jensen stated that he had joined the company’s Scientific Advisory Board. Dr. Jensen is the inventor of our patent-pending drugs and a co-applicant with the company for patents on the drugs in the United Kingdom. Although the company had planned for Dr. Jenson to assist with continuing development of its cancer treatments, he ultimately severed ties with the company.

A press release inaccurately stated that the company was “aggressively acquiring patents” and has “filed patents” for certain cancer-fighting therapies. The company acquired certain Danish patent applications and subsequently filed British patent applications for the same inventions. The applications remain pending and no patents have been issued. The press release also states that the company “could expect up to $100 million” during clinical trials and “$400 million per annum in the years following commercialization.” This statement was intended as calculation of the total potential market for a type of prostate-cancer testing that would use the company’s patent-pending intellectual property. Any suggestion that the company expected or projected total revenues in the amount stated was neither intended nor authorized.

·	A press release announced that Dr. Philip Gould was appointed to the company’s Scientific Advisory Board. Following service of the subpoena and commencement of the SEC investigation discussed above, Dr. Gould severed ties with the company.

·	A press release announced that the company was “preparing for patent application filings” in the U.S. and the E.U. for its prostaganin-based invention. No patent applications were filed in the U.S. or the E.U.

A press release announcing the company’s letter of intent with Prime Bioresearch, Inc. also refers to the company’s “expectations of reaching 100m+ revenue in year 3.” This statement reflects the company’s internal calculation of the total potential market for a type of prostate-cancer testing that would use the company’s patent-pending intellectual property. Any suggestion that the company expected or projected total revenues in the amount stated was neither intended nor unauthorized.

Genova Biotherapeutics, Inc. (Formerly known as Kinder Travel Inc.) Unaudited Notes to the Financial Statements (In Canadian Dollars)

Note 1 – Description of Business

Genova Biotherapeutics, Inc. (the "Company") was incorporated under the laws of the state of Nevada as Kinder Travel Inc. The Company changed its name on April 24, 2009.

The Company is a biotechnological drug development company with a focus on identifying, evaluating and acquiring new promising drugs for treatment and prevention of oncological and infectious diseases in human beings. Prior to that, the Company was a full-service travel agency, offering the full range of travel services including corporate travel, vacations, cruise holidays, and group tours.

On April 20, 2009, the Company acquired the right, title and interest in three medical patents for the treatment of prostate and breast cancers. This transaction is explained in detail in Note 7.

Effective July 1, 2009, the Company disposed of its travel related business assets. See Note 9.

Note 2 – Basis of Presentation

The accompanying unaudited interim consolidated financial statements of Genova Biotherapeutics, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the Company’s audited 2008 annual financial statements and notes thereto filed with the SEC on form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the result of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure required in the Company’s 2008 annual financial statements have been omitted.

Note 3 - Going Concern

The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business for the foreseeable future. Since inception, the Company has accumulated losses aggregating to $180,800 and has insufficient working capital to meet operating needs for the next twelve months as of June 30, 2009, all of which raise substantial doubt about the Company’s ability to continue as a going concern.

Note 4 - Long-Term Debt

The Company has a note payable to a bank. The note is secured by a vehicle, bears interest at 7.89% per year and requires monthly payments of $226 until June 2, 2010, at which time all remaining principal is due in full.

Note 5 – Shareholder Loans

As of June 30, 2009 and December 31, 2008, the total due to shareholders was $41,759 and $31,273, respectively. These loans are unsecured, non-interest bearing, and have no specific repayment terms. Imputed interest of $758 was calculated at a rate of 7.89% and recorded in additional paid-in capital at June 30, 2009.

Note 6 – Related Party Transactions

As of June 30, 2009, there are no related party transactions other than the shareholder loans.

Note 7 - Acquisition of Medical Patents

The Company approved the execution of an asset purchase agreement dated April 15, 2009 with Phoinos Oxford Lifesciences Limited, a company incorporated under the laws of the Federation of St. Kitts & Nevis, for the purchase of the right, title and interest in and to 3 medical patents. The patents will be amortized over its useful life of 17 years. Amortization for the period ending June 30, 2009 is immaterial to the financial statements.

Table of Contents

A press release announced that the company had signed an engagement with Pacific Wave Partners Limited for the raising of $5 million. Although a term sheet was entered into by the company and Pacific Wave, the planned financing did not go forward following the trading suspension and SEC investigation discussed above.

·	A press release announced that the company had signed an agreement with Bridge BioResearch Plc. Although a letter of intent was received from the Chairman of Bridge BioResearch, the CEO of that company later stated that the letter was issued without proper authority and retracted it.

·	A press release announced that a collaboration agreement had been signed by the company and Beckpharma, Ltd. Although a letter of intent was received from Beckpharma, it was later withdrawn.

·	A press release announced that the company was in “advanced negotiations” to acquire patents from TheraGlass, Ltd. No agreement was concluded with that company.

Other Significant Developments

Departure of Certain Executive Officers

Following issuance of the subpoena discussed above in September of 2009, Mr. John Savin, our former Vice President, left the company. Mr. Savin did not provide a letter of resignation or other formal communication regarding his departure. We are not aware of any specific disagreement with Mr. Savin on any matter relating to the Company’s operations, policies or practices.

Following issuance of the subpoena discussed above in September of 2009, Mr. Hyinho Jin, our former Secretary, left the company. Mr. Jin did not provide a letter of resignation or other formal communication regarding his departure. We are not aware of any specific disagreement with Mr. Jin on any matter relating to the Company’s operations, policies or practices. Following the departure of Mr. Jin, Dirk Holzhauer was appointed to serve as Secretary. Mr. Holzhauer continues to serve as a member of our Board of Directors.

Changes in Certifying Accountant

Following issuance of the subpoena discussed above in September of 2009, M&K CPAs, PLLC (the “Former Accountant”) declined to continue its engagement as the Company’s accountant. The Former Accountant’s audit reports on the financial statements of the Company for the fiscal year ended December 31, 2008 contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports on the financial statements of the Company for the fiscal year ended December 31, 2008 contained an uncertainty about the Company’s ability to continue as a going concern.

During the year ended December 31, 2008, and through the interim period ended June 30, 2009, there were no “disagreements” (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.

As payment, the Company placed in escrow an aggregate of 31,250,000 shares of its restricted common stock valued at $0.0024 USD per share, based on the trading price of the stock on April 15, 2009, for a total of $92,573 which will be subsequently transferred to the Phoinos Oxford Lifesciences Limited in ten (10) quarterly installments. Phoinos Oxford Lifesciences Limited agreed to assign the voting rights of the Shares held in escrow to Global Developments Inc., an existing shareholder of the Company.

On April 20, 2009, the due diligence by the Company and Seller was completed to the satisfaction of both parties and the Agreement was consummated. Therefore, on April 20, 2009, the right, title and interest to the Medical Patents was transferred by the Seller to the Company and the Company issued 31,250,000 shares of its resticted stock for a total of $92,573 in the record name of Global Developments Inc., a Delaware corporation, as consideration for the patents.

The 31,250,000 shares are being held by an escrow agent and 10% of the Shares will be transferred quarterly from Global Developments Inc. to Phoinos Oxford Lifesciences Limited in accordance with the terms of the Agreement.

Note 8 – Share Capital

1. On April 20, 2009, the Company issued 31,250,000 common shares at $0.0024 per share for the purchase of the rights, title, and interest in 3 medical patents pursuant to an Asset Purchase Agreement dated April 15, 2009.

2. On April 24, 2009, the authorized share capital of the company was increased from 65,000,000 shares, par value of $0.001, to 990,000,000 shares, par value $0.00001. All share capital and paid-in capital amounts have been retroactively adjusted for all periods to reflect this change in par value.

Note 9 - Subsequent events

1. On July 13, 2009, the Company’s completed a 125-for-1 forward stock split of the issued and outstanding common stock. These financial statements reflect the effects of this forward stock split.

2. On July 20, 2009, Dirk Holzhauer, a director and former officer of the Company, retired 23,953,875 shares of his common stock of the Company to acquire the Company’s travel related business assets effective July 1, 2009 pursuant to an Asset Purchase Agreement dated April 20, 2009.

Table of Contents

During the year ended December 31, 2008, and through the interim period ended June 30, 2009, there were no “reportable events” (as such term is defined in Item 304 of Regulation S-K).

On April 13, 2010, the Company provided the Former Accountant with its disclosures in this Quarterly Report on Form 10-Q disclosing the resignation of the Former Accountant and requested in writing that the Former Accountant furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. To date, the Former Accountant has not responded to the Company’s request. If and when the Former Accountant provides a response, it will be filed with the Securities and Exchange Commission.

On March 17, 2010, the company’s board of directors appointed De Joya Griffith & Company, LLC as the company’s auditor and independent accountant.

During the registrant's two most recent fiscal years, and the subsequent interim periods prior to engaging De Joya Griffith & Company, LLC, the company did not consult De Joya Griffith & Company, LLC regarding either the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the company's financial statements, or any matter that was either the subject of a disagreement or a reportable event.

Significant Equipment

We do not intend to purchase any significant equipment for the next twelve months.

Results of Operations for the three and nine months ended September 30, 2009 and September 30, 2008 and Period from July 1, 2009 (Date of Inception of Current Operations) until September 30 2009.

We generated no revenue during the three and nine months ended September 30, 2009 and the three and nine months ended September 30, 2008. In addition, we generated no revenue during the period from July 1, 2009 (inception of current operations) through September 30, 3009.

Our net operating expenses were $1,295 for the three months ending September 30, 2009. During the three months ended September 30, 2009, we experienced other income in the amount of $5,508 due a foreign exchange gain and other losses in the amount of $848 due to foreign currency translation adjustments. Our comprehensive income for the three months ended September 30, 2009 was therefore $3,365. By comparison, our operating expenses for the three months ending September 30, 2008 were $9,568, together with a loss from discontinued operations of $16,743 and a positive foreign currency translation adjustment of $392. Our comprehensive loss for the three months ended September 30, 2008 was therefore $25,919.

Our net operating expenses were $27,620 for the nine months ending September 30, 2009. During the nine months ended September 30, 2009, we experienced other income in the amount of $3,362 due a foreign exchange gain, income from discontinued operations in the amount of $15,296 and a positive foreign currency translation adjustment of $855. Our comprehensive loss for the nine months ended September 30, 2009 was therefore $8,107. By comparison, our operating expenses for the nine months ending September 30, 2008 were $12,898, together with a loss from discontinued operations of $14,415 and a negative foreign currency translation adjustment of $19. Our comprehensive loss for the nine months ended September 30, 2008 was therefore $27,332.

We recorded a comprehensive income of $3,365 for the period from July 1, 2009 (inception of current operations) to September 30, 2009.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

Genova Biotherapeutics Inc. is a corporation organized under the laws of the State of Nevada in December 2005. Initial operations commenced under the name “Kinder Travel & Tours” as a sole proprietorship in January 2005. In November 2005, Kinder Travel & Tours was incorporated under the laws of the Province of British Columbia as Kinder Travel, Inc. (“KTBC”). On December 6, 2005, Kinder Travel Inc. was incorporated under the laws of the State of Nevada. Subsequently, pursuant to the terms and provisions of an asset purchase agreement (the “Asset Purchase Agreement”) with KTBC, we acquired all of the assets and liabilities of KTBC in exchange for a convertible note of $20,000 (the “Note”). The Note was subsequently distributed to KTBC’s sole shareholder, Dirk Holzhauer, who converted the Note into 400,000 shares of our restricted common stock. After the effective date of our registration statement filed with the Securities and Exchange Commission (February 2, 2007), we commenced trading on the Over-the-Counter Bulletin Board under the symbol “KNDT:OB” on approximately July 3, 2007.

From inception, Kinder Travel Inc. had been a travel agency offering a full range of travel services including corporate travel, vacations, cruise holidays, and group tours. Since Kinder Travel Inc. was incurring continued losses in the travel industry, the Board of Directors decided it was in the best interests of the Corporation to pursue other business opportunities. Through his past contacts in the bio-medical industry, the then President of Kinder Travel Inc. initiated negotiations with Phoinos Oxford Lifesciences Limited, a company incorporated under the laws of the Federation of St. Kitts & Nevis (“Phoinis Oxford”), for the purchase of medical patents for the treatment of prostate and breast cancers. On April 15, 2009, Kinder Travel Inc. entered into an asset purchase agreement dated April 15, 2009 (the “Asset Purchase Agreement”) with Phoinos Oxford.

The Company subsequently changed its to “Genova Biotherapeutics Inc.” Our shares of common stock now trade on the Over-the-Counter Bulletin Board under the symbol “GVBP.OB”.

Please note that throughout this Quarterly Report, and unless otherwise noted, the words "we," "our," "us," the "Company," or "Kinder Travel," refers to Genova Biotherapeutics Inc.

RECENT CORPORATE DEVELOPMENTS

Forward Stock Split

On April 21, 2009, our Board of Directors pursuant to a Board of Directors meeting authorized and approved a forward stock split of one hundred and twenty five for one (125:1) of our total issued and outstanding shares of common stock (the “Forward Stock Split”).

The Forward Stock Split was effectuated based on market conditions and upon a determination by our Board of Directors that the Forward Stock Split was in our best interests and of the shareholders. Certain factors were discussed among the members of the Board of Directors concerning the need for the Forward Stock Split, including the increased potential for financing. The intent of the Forward Stock Split is to increase the marketability of our common stock.

The Forward Stock Split was effectuated on July 13, 2009 upon filing the appropriate documentation with NASDAQ. The Forward Stock Split increased our total issued and outstanding shares of common stock from 2,650,000 to approximately 331,250,000 shares of common stock.

Change in Corporate Name

The Board of Directors approved a resolution on April 21, 2009 to amend our Articles of Incorporation to change our name from “Kinder Travel Inc.” to “Genova Biotherapeutics Inc”. An amendment to our Articles of Incorporation was filed with the Nevada Secretary of State on April 24, 2009 effecting the change in name from “Kinder Travel Inc. to “Genova Biotherapeutics Inc.” See “Part II. Item 4. Submission of Matters to a Vote of Security Holders.”

The objective of the change in our corporate name was deemed necessary to more accurately reflect our proposed business activities in our name. We believe that the change in our corporate name will better communicate to the public our proposed and future nature of business operations.

Table of Contents

Liquidity and Capital Resources

As of September 30, 2009, we had total current assets of $29,617, consisting of cash in the amount of $25,204 and a note due from a director in the amount of $4,413. We had current liabilities in the amount of $60,652 as of September 30, 2009. Thus, we had a working capital deficit of $31,035 as of September 30, 2009.

Currently, we have insufficient cash to operate our business on an ongoing basis and we have no resources with which to move forward with development of our patent-pending cancer treatments. Our ability to continue operating and to make progress toward our business goals is contingent upon obtaining additional financing. We do not have any commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Going Concern

We have recurring losses and an accumulated deficit of $180,800 as of September 30, 2009. Our financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, we have no current source of revenue. Without realization of additional capital, it would be unlikely for us to continue as a going concern.

Off Balance Sheet Arrangements

As of September 30, 2009, there were no off balance sheet arrangements.

Increase in Authorized Capital Structure

The Board of Directors approved a resolution on April 21, 2009 to amend our Articles of Incorporation to increase our authorized capital structure from 65,000,000 shares of common stock with a par value of $0.001 to 1,000,000,000 shares of common stock with a par value of $0.00001 per share (the “Change in Capital Structure”). An amendment to our Articles of Incorporation was filed with the Nevada Secretary of State on April 24, 2009 effecting the Change in Capital Structure. See “See “Part II. Item 4. Submission of Matters to a Vote of Security Holders.”

The objective of the Change in Capital Structure was to allow for future issuances of our common stock in accordance with forward stock splits, proposed equity financings, debt settlement, and contractual provisions. Our Board of Directors believed that an increase in the authorized capital structure would increase our marketability and liquidity in the future.

Cancellation of Shares

On July 20, 2009, our prior executive officer, Dirk Holzhauer, agreed to return an aggregate 23,953,875 shares of our common stock. Mr. Holzhauer agreed to return the shares of common stock to us in return for the acquisition of our travel related business assets. See “Current Business Operations” below.

CURRENT BUSINESS OPERATIONS

Our Board of Directors engaged in an analysis of the current travel industry including, but not limited to: (i) general economic conditions relating to travel; (ii) current appeal of websites to businesses and travelers to purchase significantly more travel products online than previously; (iii) growth of the usage of the Internet as a medium of commerce for travel products; and (iv) current travel industry competition. Our Board of Directors determined that we would not grow as a business as expected within the travel industry. Therefore, our Board of Directors engaged in discussions and negotiations regarding a change in our strategic business operational planning. These discussions lead to a decision by our Board of Directors to divest and sell our travel related products and assets and acquire the right, title and interest in and to three medical patents as described below.

Asset Purchase Agreement

In furtherance of strategic planning, our Board of Directors engaged in negotiations regarding a transaction in which we would acquire the right, title and interest in and to three separate medical patents (collectively, the “Medical Patents”), owned by Phoinos Oxford.

Our Board of Directors approved the execution of the Asset Purchase Agreement with Phoinos Oxford. Under the terms and provisions of the Asset Purchase Agreement and that certain escrow agreement dated April 15, 2009 between us and Phoinos Oxford (the “Escrow Agreement”): (i) we purchased the right, title and interest in and to the Medical Patents for $92,573 (the “Purchase Price”); (ii) as payment of the Purchase Price for the Medical Patents, we placed in escrow an aggregate of 250,000 shares of our restricted common stock valued at $0.30 per share, as increased to 31,250,000 shares of common stock in accordance with the Forward Stock Split (the “Escrow Shares”), which Shares are to be subsequently transferred to Phoinos Oxford in ten (10) quarterly installments; and (iii) Phoinos Oxford agrees to assign the voting rights of the Shares held in escrow to Global Developments Inc., one of our existing shareholders (“Global”). The Escrow Shares are being held by Global as escrow agent and 10% of the Escrow Shares will be transferred quarterly from Global to Phoinos Oxford in accordance with the terms of the Escrow Agreement. See “Part II. Item 2. Unregistered Sales of Securities and Use of Proceeds.”

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4T. Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2009. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, Aaron Whiteman. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2009, our disclosure controls and procedures are effective. There have been no changes in our internal controls over financial reporting during the quarter ended September 30, 2009.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Limitations on the Effectiveness of Internal Controls

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving our objectives and our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective at that reasonable assurance level. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the internal control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

The Agreement

As discussed above, our Board of Directors was further engaged in discussions and negotiations regarding strategic business operational planning pertaining to a divesture and sale of our travel related products and assets including, but not limited to, suppliers list, customer and vendor lists, records, tradename, trademark and trade secrets, trade practices, goodwill, clients, equipment, furniture, machinery, fixtures, supplies, inventory, existing contract and tangible personal property (the “Assets”). Our Board of Directors furthermore engaged in several analysis regarding the fair market value of our Assets based primarily upon a consideration of two valuations of a business using the tangible asset valuation method and the industry multiplier valuation method in connection with the offer and sale of our Assets, and determined that the Board of Directors should be authorized to divest us of our travel business and related Assets at a price not less than the midpoint of those two valuation methods. Our Board of Directors determined that our Assets are to be valued at $57,489.

Effective on April 20, 2009, our Board of Directors approved the execution of an asset purchase agreement dated April 20, 2009 (the “Agreement”) with Dirk Holzhauer, one of our shareholders, a director, and a former officer (the “Purchaser”). In accordance with the terms and provisions of the Agreement: (i) we sold to the Purchaser the Assets for a purchase price of $57,489 (the “Purchase Price”); and (ii) as payment for the Assets, the Purchaser returned to us an aggregate of 191,631 shares of our common stock held of record by the Purchaser valued at $0.30 per share based upon the last trade price of $0.30 of our shares of common stock as traded on the OTC Bulletin Board as of October 8, 2008.

The Asset Purchase Agreement was subject to shareholder approval, which was provided. See “Part II. See “Part II. Item 4. Submission of Matters to a Vote of Security Holders.”

On July 20, 2009, Dirk Holzhauer, a director and former officer of the Company, retired 23,953,875 shares of his common stock of the Company to acquire the Company’s travel related business assets effective July 1, 2009 pursuant to an Asset Purchase Agreement dated April 20, 2009.

RESULTS OF OPERATION

We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities.

Six Month Period Ended June 30, 2009 Compared to Six Month Period Ended June 30, 2008.

Our comprehensive loss during the six month period ended June 30, 2009 was ($11,472) compared to a comprehensive loss of ($1,412) during the six month period ended June 30, 2008 (an increase of $10,060). This is primarily attributable to a decrease in gross sales during the six month period ended June 30, 2009 compared to the six month period ended June 30, 2008, where we generated gross sales income of $125,698 and $139,405, respectively. Cost of sales increased during the six month period ended June 30, 2009 to $55,517 from $32,148 during the six month period ended June 30, 2008, resulting in net sales, or a gross margin, of $70,181 for the six month period ended June 30, 2009 compared to $107,258 for the same period in 2008.

During the six month period ended June 30, 2009, we incurred general and administrative expenses of approximately $83,356 compared to $108,259 incurred during the six month period ended June 30, 2008 (a decrease of $24,903). The decrease in expenses is attributable to a reduction in payroll, professional, as well as general and administrative expenses. General and administrative expenses generally include corporate overhead, financial and administrative contracted services, marketing, and consulting costs.

Foreign currency translation adjustment costs incurred during the six month periods ended June 30, 2009 and June 30, 2008 of $1,703 and ($411), respectively, were recorded. This resulted in a comprehensive loss of ($11,472) or ($0.00) per share for the six month period ended June 30, 2009 compared to a comprehensive loss of ($1,412) or ($0.00) per share for the six month period ended June 30, 2008. The weighted average number of shares outstanding was 313,121,547 for the six month period ended June 30, 2009 compared to 300,000,000 for the six month period ended June 30, 2008 (taking into consideration the Forward Stock Split).

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A: Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted to our security holders for a vote, or through the solicitation of proxies, during the quarterly period ended September 30, 2009.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Three Month Period Ended June 30, 2009 Compared to Three Month Period Ended June 30, 2008.

Our comprehensive loss during the three month period ended June 30, 2009 was ($13,560) compared to a comprehensive loss of ($3,618) during the six month period ended June 30, 2008 (an increase of $9,942). This is primarily attributable to a decrease in gross sales during the three month period ended June 30, 2009 compared to the three month period ended June 30, 2008, where we generated gross sales income of $58,851 and $67,860, respectively. Cost of sales increased during the three month period ended June 30, 2009 to $22,553 from $17,447 during the three month period ended June 30, 2008, resulting in net sales, or a gross margin, of $36,298 for the three month period ended June 30, 2009 compared to $50,413 for the same period in 2008.

During the three month period ended June 30, 2009, we incurred expenses of approximately $51,465 compared to $53,414 incurred during the three month period ended June 30, 2008 (a slight decrease of $1,949). General and administrative expenses incurred during the three month period ended June 30, 2009 compared to the three month period ended June 30, 2008 decreased primarily due to the decrease in expenses associated with payroll and general and administrative.

Foreign currency translation adjustment costs incurred during the three month periods ended June 30, 2009 and June 30, 2008 of $1,607 and ($617), respectively, were recorded. This resulted in a comprehensive loss of ($13,550) or ($0.0) per share for the three month period ended June 30, 2009 compared to a comprehensive loss of ($3,618) or ($0.00) per share for the three month period ended June 30, 2008. The weighted average number of shares outstanding was 326,098,901 for the three month period ended June 30, 2009 compared to 300,000,000 for the three month period ended June 30, 2008 (taking into consideration the Forward Stock Split).

LIQUIDITY AND CAPITAL RESOURCES

As at June 30, 2009

As at the six month period ended June 30, 2009, our current assets were $35,049 and our current liabilities were $112,847, which resulted in a working capital deficiency of ($77,798). As at the six month period ended June 30, 2009, current assets were comprised of: (i) $28,884 in cash; and (ii) $6,165 in accounts receivable (net of allowance for doubtful accounts). As at the six month period ended June 30, 2009, current liabilities were comprised of: (i) $45,239 in accounts payable; (ii) $2,906 in accrued liabilities; (iii) $2,470 in payroll liabilities; (iv) $613 in sales tax payable; (v) $41,759 in shareholders’ loan; and (vi) $19,860 in current portion of long-term debt.

As at the six month period ended June 30, 2009, our total assets were $159,681 compared to $59,954. This increase was primarily due to the acquisition of the three medical patents. See “Asset Purchase Agreement” above.

As at the six month period ended June 30, 2009, our total liabilities were $112,847 comprised entirely of current liabilities. The increase in liabilities during the six month period ended June 30, 2009 from fiscal year ended December 31, 2008 was primarily due to an increase in accounts payable and shareholders’ loans. See “Material Commitments”.

Stockholders’ equity increased from ($35,680) for fiscal year ended December 31, 2008 to stockholders’ equity of $46,834 for the six month period ended June 30, 2009.

Cash Flows from Operating Activities

We have not generated positive cash flows from operating activities. For the six month period ended June 30, 2009, net cash flows used in operating activities was ($3,967), attributable primarily to our net loss of ($13,175). For the six month period ended June 30, 2008, net cash flows used in operating activities was ($10,680), attributable primarily to an increases in accounts receivable.

Table of Contents

12SIGNATURES

~~Cash~~In ~~Flows~~accordance ~~from~~with ~~Investing~~the ~~Activities~~requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

For the six month periods ended June 30, 2009 and June 30, 2008, net cash flows used in investing activities was $-0-.

	Genova Biotherapeutics, Inc.

Date:	April 16, 2010

	By: /s/ Aaron Whiteman Aaron Whiteman Title: Chief Executive Officer and Chief Financial Officer

Cash Flows from Financing Activities

We have financed our operations primarily from either advancements or the issuance of equity and debt instruments. For the six month period ended June 30, 2009, net cash flows provided from financing activities was $9,928 compared to $9,096 for the six month period ended June 30, 2008. Cash flows from financing activities for the six month period ended June 30, 2009 consisted of $19,907 in borrowings on debt offset by ($9,979) in payments on debt. Cash flows from financing activities for the six month period ended June 30, 2008 consisted of $113,135 in borrowings on debt offset by ($104,040) in payments on debt.

We expect that working capital requirements will continue to be funded through a combination of our existing funds, shareholder loans, and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.

PLAN OF OPERATION AND FUNDING

Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next six months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to the development, marketing and distribution of products relating to the Medical Patents. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

MATERIAL COMMITMENTS

As of June 30, 2009, the total due to shareholders was $41,759. These loans are unsecured, non-interest beading and have no specific repayment terms. Imputed interest of $758 was calculated at a rate of 7.89% and recorded in additional paid-in capital at June 30, 2009.

PURCHASE OF SIGNIFICANT EQUIPMENT

We do not intend to purchase any significant equipment during the next twelve months.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

GOING CONCERN

The independent auditors' report accompanying our December 31, 2008 and December 31, 2007 financial statements contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared "assuming that we will continue as a going concern," which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

Table of Contents

ITEM III. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Market risk represents the risk of loss that may impact our financial position, results of operations or cash flows due to adverse change in foreign currency and interest rates.

Exchange Rate

Our reporting currency is the Canadian Dollar. In the event we engage in business operations within the United States and outside of Canada, the fluctuation of exchange rates may have positive or negative impacts on our results of operations. However, since our business operations as of June 30, 2009 were primarily conducted within Canada, revenue and expenses are denominated in Canadian Dollar, and the net income effect of appreciation and devaluation of the currency against the Canadian would be limited to our costs of engaging in business operations outside of Canada.

Interest Rate

Interest rates in Canada are generally controlled. Any potential future loans will relate mainly to the development and marketing of our Medical Patents and will be mainly short-term. However our debt may be likely to rise in connection with expansion of operations and if interest rates were to rise at the same time, this could become a significant impact on our operating and financing activities. We have not entered into derivative contracts either to hedge existing risks of for speculative purposes.

ITEM IV. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

We have performed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer (CEO)/Chief Financial Officer (CFO), of the effectiveness of our disclosure controls and procedures, (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our management, including our CEO/CFO, concluded that our disclosure controls and procedures were not effective as of June 30, 2009 to provide reasonable assurance that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Management’s Annual Report on Internal Control Over Financial reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision and with the participation of our management, including our CEO/CFO, we evaluated the effectiveness of our internal control over financial reporting as of June 30, 2009. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. Management noted no changes in the following material weaknesses stated in the 10-K:

1. As of June 30, 2009, we did not maintain effective controls over the control environment. Specifically we have not developed and effectively communicated to our employees its accounting policies and procedures. This has resulted in inconsistent practices. Further, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-B. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

Table of Contents

2. As of June 30, 2009, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

3. As of June 30, 2009, we did not maintain effective controls over receivables and accrued liabilities. Specifically, controls were not designed and in place to ensure that accrued liabilities were properly recorded and that receivables were evaluated for collectibility. Accordingly, management has determined that this control deficiency constitutes a material weakness.

This Quarterly Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this Quarterly Report on Form 10-Q.

Inherent Limitations on Effectiveness of Controls

We believe that a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, and our CEO/CFO has concluded that these controls and procedures are effective at the “reasonable assurance” level.

Changes in internal controls

No significant changes were implemented in our internal controls over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

AUDIT COMMITTEE

Our Board of Directors has not established an audit committee nor do we have an audit committee financial expert. The respective role of an audit committee has been conducted by our Board of Directors. We are contemplating establishment of an audit committee during fiscal year 2009. When established, the audit committee's primary function will be to provide advice with respect to our financial matters and to assist our Board of Directors in fulfilling its oversight responsibilities regarding finance, accounting, and legal compliance. The audit committee's primary duties and responsibilities will be to: (i) serve as an independent and objective party to monitor our financial reporting process and internal control system; (ii) review and appraise the audit efforts of our independent accountants; (iii) evaluate our quarterly financial performance as well as its compliance with laws and regulations; (iv) oversee management's establishment and enforcement of financial policies and business practices; and (v) provide an open avenue of communication among the independent accountants, management and our Board of Directors.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

ITEM IA. RISK FACTORS

No report required.

Table of Contents

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

Effective on April 15, 2009, our Board of Directors approved the execution of the Asset Purchase Agreement with the Seller. On April 20, 2009, the right, title and interest to the Medical Patents was transferred by Phoinos Oxford to us and we issued the 250,000 Pre-Forward Stock Split (31,250,000 Post-Forward Stock Split) shares of our restricted stock to Phoinos Oxford as consideration for the Medical Patents.

Under the terms and provisions of the Asset Purchase Agreement and the Escrow Agreement, we placed in escrow the 250,000 Pre-Forward Stock Split (31,250,000 Post-Forward Stock Split) shares of our restricted common stock in escrow (the “Escrow Shares”). The Escrow Shares are to be subsequently transferred to Phoinos Oxford in ten (10) quarterly installments and Phoinos Oxford agreed to assign the voting rights of the Escrow Shares to Global. The Escrow Shares are being held by Global as escrow agent and 10% of the Escrow Shares will be transferred quarterly from Global to Phoinos Oxford in accordance with the terms of the Escrow Agreement.

The issuance of the shares to the Seller was in reliance on Rule 903 of Regulation S promulgated under the Securities Act of 1933, as amended. The securities issued in accordance with the Asset Purchase Agreement have not been registered under the Securities Act or under any state securities laws and may not be offered or sold without registration with the United States Securities and Exchange Commission or an applicable exemption from the registration requirements. There were no finders' fees or commission payable by us upon consummation of the transaction.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

No report required.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On April 20, 2009, our Board of Directors authorized and approved, subject to shareholder approval, certain corporate actions, which the Board of Directors deemed to be in our best interests and our shareholders. Our Board of Directors further authorized the preparation and circulation of an information statement dated April 21, 2009 (the “Information Statement”) and a shareholders' consent to certain shareholders holding a majority of the total issued and outstanding shares of our common stock (the “Consenting Shareholders”). The preliminary Information Statement was filed with the Securities and Exchange Commission on April 21, 2009 and a definitive Information Statements was filed with the Securities and Exchange Commission on July 1, 2009 and subsequently provided to our shareholders.

The matters upon which action was taken was: (i) approval of the divesture and sale of the our travel related products and assets in accordance with the terms and provisions of the Agreement with Dirk Holzhauer; (ii) approval of the amendment (the “Name Change Amendment”) to our Articles of Incorporation, as amended (the “Articles of Incorporation”) to effectuate a change in our name of the Corporation (the “Name Change”) to Genova Biotherapeutics Inc.; (iii) approval of an amendment (the “Change in Capital Structure Amendment”) to our Articles of Incorporation to amend our authorized capital structure from 65,000,000 shares of common stock with a par value of $0.001 per share to 1,000,000,000 shares of common stock with a par value $0.00001 per share; and (iv) approval and ratification of the appointment of the current members of our Board of Directors and to duly appoint Hyunho Jin as a member of our Board of Directors to serve until his successor is duly appointed.

The above actions were approved by our Board of Directors and the Consenting Holders on April 20, 2009 and April 21, 2009 respectively. Accordingly, we have secured the necessary authorization for the above actions.

Table of Contents

ITEM 5. OTHER INFORMATION

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On April 10, 2009, Dirk Holzhauer, our sole director, appointed Mr. Aaron Whiteman to join the Board to fill a vacancy created by the resignation, in September 2008 of the only other member of the Board of Directors. Mr. Whiteman accepted the appointment on April 10, 2009.

On April 13, 2009, our Board of Directors appointed Mr. Aaron Whiteman as our President/Chief Executive Officer and Treasurer/Chief Financial Officer, Dr. John Savin as our Vice President and Mr. Hyunho Jin as our Secretary. Mr. Whiteman, Dr. Savin, and Mr. Jin all accepted their respective appointments on April 13, 2009. On April 13, 2009, Mr. Dirk Holzhauer, our incumbent President, Vice President, Treasurer and Secretary, resigned. The resignation did not involve any disagreement with us. Mr. Holzhauer will remain one of our directors.

On April 21, 2009, in accordance with the approval by the Consenting Holders and the provisions of the Information Statement, Hyunho Jin was appointed to our Board of Directors.

Therefore, as a result of the above changes, our officers and directors are as follows:

Name Title Aaron Whiteman President/Chief Executive Officer/Treasurer/Chief FinancialOfficer and a director John Savin Vice President Hyunho Jin Secretary and a director Dirk Holzhauer Director

Aaron Whiteman. Mr. Aaron Whiteman holds a Bachelors of Law Degree from Oxford University and an MBA from the London School of Economics. Most recently, he served as a Vice President of Reliance Biotech, an Indian medical research company, responsible for business development and expansion into the European, Middle Eastern, and African regions. Prior to that, from May 2002 through May 2007, Aaron Whiteman was a Vice President of Viranative AB, where he was responsible for promotion of the company’s products to strategic partners in the Sub-Saharan region. During his tenure, he successfully secured licensing agreements and commercial alliances with pharmaceutical giants Pharmacia (Upjohn), Astra Zeneca, and Glaxo Smith Kline. He has also held various executive, board, and advisory positions in the telecommunications industry.

John Savin. Dr. Savin was the chief executive officer of Physiomics plc, a cancer research and simulation company he founded in 2001, which was quoted on the London Alternative Investment Market in 2004. As the chief executive officer, he created a multi-disciplinary research and development team, raised equity funding, marketed to major pharmaceutical and biotech companies in Europe and the United Sates, developed sales pipelines, and established a global marketing and technology strategic alliance with Bayer AG. Dr. Savin left Physiomics in 2006 to found Wendover Technology, which provides consulting services to the biotechnology industry. Wendover Technology services include investment reports, due diligence on mergers and acquisitions, strategic planning, project management, and negotiating licensing agreements. Prior to Physiomics, Dr. Savin was a top-rated investment analyst in the pharmaceutical and biotech sector in London. He has also worked as a high-level consultant and has an industry background in international marketing of life science products and DNA diagnostics. Dr. Savin was awarded a Ph.D. in organic chemistry from Nottingham University and has an MBA with a distinction in international business and corporate strategy. He has been a director of various companies including Biotechconvergence, Wendover Technology, Zetagen and Greig Middleton & Co.

Hyunho Jin. Following three years of compulsory military service, Mr. Hyunho Jin attended Youngjin College in Seoul, Korea where he received a management diploma. He was hired by the Hansung office of BTM Services Corp., a management consulting company, where he was responsible for business development of their regional office. He held that position for two years before being moved, in May 2000, to the Bohun office, where he was responsible for international business development, specifically expansion into South East Asia.

Table of Contents

Dirk Holzhauer. After completing two years of service in the German army, Mr. Holzhauer attended Werner-von-Siemenns-Berufskolleg in Cologne where he received a Bachelors Degree in Business Economics. This was followed by several business ventures in Germany before he emigrated to Canada in 1996. Since then he has served as an officer and director of both public and private companies in the United States and Canada, including his position as founding officer, director, and shareholder of Kinder Travel Inc. since 2005. Mr. Holzhauer is a citizen of Germany and a resident of Canada.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

Exhibits
10.01	Asset Purchase Agreement dated April 20, 2009 between Kinder Travel Inc. and Dirk Holzhauer. (1)
10.2	Asset Purchase Agreement dated April 15, 2009 between Kinder Travel Inc. andPhoinos Oxford Lifesciences Limited. (2)
31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act of1934 Rule 13a-14(a) or 15d-14(a).
31.2	Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).
32.1	Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.
(1)	Incorporated by reference to the exhibit filed with our Current Report on Form 8-K filed with the Securities and Exchange Commission on April 21, 2009.
(2)	Incorporated by reference to the exhibit filed with our Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2009.

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GENOVA BIOTHERAPEUTICS INC.
Dated: August 10, 2009	By:	/s/ Aaron Whiteman
		Aaron Whiteman, President and Chief Executive Officer

Dated: August 10, 2009	By:	/s/ Aaron Whiteman
		Aaron Whiteman, President and Chief Executive Officer

Filing Compare · Genova Biotherapeutics Inc.